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BACKGROUND: TREATMEN The contribution of eosinophilic esophagitis (EoE) to refractory gastroesophageal reflux
disease (GERD) remains unknown. When EoE and GERD overlap, the clinical, endoscopic and histological findings
are nonspecific and cannot be used to distinguish between the two disorders. Limited data are available on this
topic, and the interaction between EoE and GERD is a matter of debate.
AIM: We have conducted a prospective study of adult patients with refractory GERD to evaluate the overlap of
reflux and EoE.
METHODS: Between July 2006 and June 2008, we consecutively and prospectively enrolled 130 male and female
patients aged 18 to 70 years old who experienced persistent heartburn and/or regurgitation more than twice a
week over the last 30 days while undergoing at least six consecutive weeks of omeprazole treatment (at least 40 mg
once a day). The patients underwent an upper digestive endoscopy with esophageal biopsy, and intraepithelial
eosinophils were counted after hematoxylin/eosin staining. The diagnosis of EoE was based on the presence of 20 or
more eosinophils per high-power field (eo/HPF) in esophageal biopsies.
RESULTS: Among the 103 studied patients, 79 (76.7%) were females. The patients had a mean age of 45.5 years and
a median age of 47 years. Endoscopy was normal in 83.5% of patients, and erosive esophagitis was found in 12.6%.
Only one patient presented lesions suggestive of EoE. Histological examination revealed .20 eo/HPF in this patient.
CONCLUSION: Our results demonstrated a low prevalence of EoE among patients with refractory GERD undergoing
omeprazole treatment.
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INTRODUCTION
The persistence of typical gastroesophageal reflux disease
(GERD) symptoms has become frequent in medical practice.
GERD presents a major challenge with respect to patient
follow-up because of the high cost of investigation,
1 its
association with functional involvement and the presence of
symptoms associated with dyspeptic conditions.
2 The
literature has reported cases presenting with typical GERD
symptoms (even without previous endoscopic or pH-metric
investigation) that last at least two days a week for 30 days
or more than once a week for three months and that are
refractory to clinical treatment at any intensity or frequency,
despite receiving a daily proton pump inhibitor dose of at
least 40 mg.
3
The refractory nature of the disorder can result from
several factors, including treatment nonadherence,
4 the
presence of acid reflux or bile/duodenogastric reflux,
visceral hypersensitivity, functional disease, psychological
comorbidities and delayed gastric emptying.
1
Over the last ten years, eosinophilic esophagitis (EoE) has
been increasingly studied. It has recently been associated
with GERD.
3,5,6
The most frequent EoE manifestations in adults are
dysphagia,
7 food impaction and chest pain. Heartburn is
also present in up to 20% of cases, and it requires a
differential diagnosis from GERD.
8-10
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557Early studies observed that 1 to 15% of patients diagnosed
with primary GERD presented with EoE.
11,12 Among
patients who underwent endoscopy, 6.5% had EoE;
13 this
value increased to 8.8% among patients with GERD.
14 It is
now suggested that the EoE is more prevalent among GERD
patients who do not respond to treatment with PPI.
7,15
The EoE prevalence in adults is not completely described
in the literature when typical symptoms, such as heartburn
and regurgitation, are mentioned. Accordingly, we pro-
posed to determine the EoE prevalence in patients with
persistent heartburn and/or regurgitation undergoing
treatment with omeprazole.
MATERIAL AND METHODS
A total of 130 male and female patients aged 18 to 70 years
old with a clinical diagnosis of refractory GERD were
consecutively and prospectively enrolled between July 2006
and June 2008.
The inclusion criterion was the persistence of heartburn
and/or regurgitation more than twice a week over the last
30 days while undergoing omeprazole treatment (at least
40 mg once a day) for at least six consecutive weeks.
1,3
Patients with a previous history of upper digestive tract
surgery, decompensated chronic diseases and/or consump-
tive diseases; pregnant or nursing women; and patients with
a previous upper digestive endoscopy showing active
peptic ulcer, esophageal diverticulum, Barrett’s esophagus
or esophageal obstruction were excluded from the study.
The study was submitted for the approval of the Ethics
Committee on Research, and all patients signed an informed
consent form.
All patients attended three appointments to classify their
symptoms and to receive information about PPI adminis-
tration and the clinical trial, including signs of a potential
allergic reaction to the treatment. Patients who developed
only atypical symptoms of persistence and those who were
taking corticosteroids were excluded.
All patients underwent an upper digestive endoscopy
(UDE) with esophageal biopsy and laboratory assessment.
The Los Angeles endoscopic classification for GERD
16 was
used for the upper digestive endoscopy assessment. Hiatal
hernia was defined as a protrusion larger than two centimeters
above the esophageal-gastric transition.
All patients underwent esophageal biopsy five and 10 cm
from the esophageal-gastric transition. Two samples were
collected from each site, and one extra sample was taken
when mucosal alterations (corrugations, erosions, signs of
acanthosisorfungusor granular lesions) wereobserved; thus,
five biopsy samples were taken to increase the diagnostic
sensitivity. Instead of small intestine biopsy, we performed
two stomach biopsies to rule out eosinophilic gastroenteritis,
due to the high incidence of enteroparasitosis in Brazil.
All anatomopathological assessments were completed,
and intraepithelial eosinophils (eo) were counted in up to
six high-power fields (hpf: 0.158 mm
2) (x400) after hema-
toxylin/eosin staining. All histological features were ana-
lyzed by a single pathologist blinded to the diagnosis and
were reviewed by the researcher.
A diagnosis of eosinophilic esophagitis was established
when the number of intraepithelial eosinophils in the
esophagus was $20 eo/HPF and was associated with the
absence of eosinophils in the gastric mucosa, which increased
the diagnosticspecificity,assuggestedin the 2007 consensus.
7
Blood samples were collected to determine the serum
eosinophil level (complete blood count) and total IgE level.
Three consecutive stool assessments were conducted to rule
out parasitic infestation.
RESULTS
Overall, 130 patients were evaluated in the study. Of
these, 25 were excluded because they used budesonide
inhalers, and two were excluded because they refused to
undergo upper digestive endoscopy (UDE) with biopsy (see
figure 1).
Among the 103 studied patients, 79 (76.7%) were female.
Patients had a mean age of 45.5 years and a median age of
47 years.
The mean PPI dose was 76¡9.1 (median of 80) mg per
day (40 mg twice a day) for a mean time of 36.8¡28.5
(median of 24) weeks. The characteristics of study popula-
tion are presented in Table 1.
Figure 1 - Patient selection flowchart GERD: gastroesophageal reflux disease; PPI: proton pump inhibitor; UDE; upper digestive
endoscopy; eo: eosinophils.
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558Laboratory assessment results, including eosinophil
count, serum IgE level and the presence of enteroparasitosis,
are presented in Table 2.
No esophageal lesion was observed on upper digestive
endoscopy in 86 patients (83.5%), and 13 other patients
(12.6%) presented persistent of erosive esophagitis (Los
Angeles grade A) while undergoing treatment with PPI.
Four patients presented other esophageal lesions, and only
one presented lesions suggestive of EoE (i.e., a granular
aspect and esophageal mucosa corrugations).
The esophageal biopsy outcomes, which included intrae-
pithelial eosinophils counts in a high-power field, identified
only one patient with EoE whose counts the distal and
proximal thirds of the esophagus were .20 eo/HPF.
Enteroparasitosis and gastroenteritis diagnoses were ruled
out for this patient.
The other 102 patients presented a low eosinophil count,
with a maximum of three eo/HPF, and no eosinophilic
microabscesses were observed.Therefore, the EoE occur-
rence among patients previously diagnosed with GERD
with persistent heartburn and/or regurgitation while
undergoing PPI treatment was one in 103 studied patients
(0.97%).
The patient presenting with EoE was a 23-year–old man.
He used 80 mg of omeprazole, and he had a diagnosis of
allergies with rhinitis. His plasmatic eosinophil count was
100, and his total IgE was 79. We excluded the possibility of
viral and fungal infections. The endoscopy revealed a
granular aspect and esophageal mucosa corrugations; the
biopsy showed 32 and 23 eo/HPF in the distal and proximal
regions of the esophagus, respectively. The patient under-
went skin prick and patch tests, and the results indicated
that he was sensitive to eggplant. Eggplant was excluded
from his diet, and he was treated with 20 mg of
montelukast. After three months of treatment, a new biopsy
was conducted, and only one eosinophil was found.
DISCUSSION
During GERD treatment, PPIs are the most common and
effectiveclassofdrugsprescribedtohealerosiveesophagitis;
however, clinical trials have shown that J of patients with
erosive GERD have persistent heartburn symptoms after 30
days of treatment.
17 Double doses and prolonged treatment
have been described as factors that increase treatment
efficacy,
18 thus contributing to the fact that two of the five
most commonly sold medications in the USA are PPIs. PPI
sales per year have doubled since 1999.
19
Nevertheless, PPI therapeutic failure has become one of
the greatest clinical challenges in the management of
patients with GERD.
1
The definition of refractoriness to PPI is controversial and
may be related to the persistence of symptoms (thus
including patients with functional heartburn), the persis-
tence of acid reflux upon pH-metry (thus including only
patients with acid reflux) or even the presence of nonacid
reflux upon impedance/pH-metry (which would also
include patients with functional heartburn not defined by
the impedance/pH-metry assessment).
Table 1 - Study population characteristics PPI: proton
pump inhibitor.
Frequency %
Sex
Female 79 76.7
Male 24 23.3
Age, years
18-30 8 7.8
31-40 23 22.3
41-50 36 35
51-60 30 29.1
More than 60 6 5.8
Escolarity
,8 years 64 62.1
.8 years 39 37.9
PPI dose
40 mg 1 0.97
60 mg 27 26.2
More than 80 mg 75 72.8
Tabagism
Yes 12 11.7
No 91 88.3
Symptoms
Dysphagia 59 57.3
Hoarseness 61 59.2
Postprandial fullness 68 66
Epigastralgia 70 68
Nausea 56 34.9
Globus hystericus 42 40.8
Coughing 36 34.9
Chest pain 34 33
Allergy
Yes 67 65
No 36 35
Comorbidity
Hypertension 36 35
Diabetes mellitus 3 2.9
Depression 31 30.1
Fibromyalgia 6 5.8
Asthma 7 6.8
Thyroid disease 8 7.8
Table 2 - Eosinophil (eo) count and serum IgE levels in patients with and without parasitosis.
Frequency % IgE medium eo plasmatic
Patients with enteroparasitosis 37 36 ------------------ -----------------
Schistosoma mansoni 3 2.01 3416 367
Strongyloides stercoralis 3 2.91 261 800
Ancylostoma duodenale 1 0.97 5 500
Giardia lamblia 1 0.97 72 100
Entamoeba histolytica 2 1.9 90 200
Entamoeba coli 13 12.6 179 133
Hymenolepsis nana 19 18.4 62 188
Blastocystis hominis 9 8.7 64 100
Others 2 1.9 23 250
Average ---------- ---- 463 293
Patients without enteroparasitosis 66 64 366 302
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symptoms do not respond properly to a minimum PPI
dose,
20 as lower refractoriness rates are observed when
patients take 40 mg/day of omeprazole. Accordingly, we
chose to include in the present study patients who took
40 mg/day of omeprazole but experienced persistent typical
symptoms (heartburn and/or regurgitation) at any intensity
or frequency for at least two days a week over the last 30
days or more than once a week over the last three months.
1,3
The main causes for therapeutic failure (i.e., incorrect
drug administration and poor treatment adherence) were
ruled out by supplying the medication, free of charge,
throughout the entire pre-inclusion period of the study and
by providing information on the correct time to take the
medication. The patients were followed for at least six
weeks by the researcher to monitor treatment adherence.
Eosinophilic esophagitis has been recently reported as a
cause of GERD refractoriness. The present study defined
GERD refractoriness specifically in terms of typical symp-
toms, excluding patients who only developed dysphagia or
food impaction (the prevalent symptoms of EoE) with
endoscopic findings and eosinophil counts that were not
specific to EoE.
21 Previous reports suggest that EoE would
be high among patients with refractory GERD.
14 We
decided to perform four esophageal biopsies at two
different levels, which could raise doubts about diagnostic
sensitivity; however, we emphasize that other biopsies
conducted when any mucosal alteration was observed, thus
increasing the sensitivity to almost 100%. Because the
outcomes obtained in patients with GERD undergoing
treatment with omeprazole were negligible (up to
three eo/HPF), we believe a sufficient number of biopsies
were performed to produce a differential diagnosis.
7
Furthermore, none of the patients presented an eosinophil
count between 15 and 20 eo/HPF, indicating that the 20 eo/
HPF cut-off for diagnosis was correct.
It is important to emphasize that this is the first
prospective study to exclude the main cause of refractori-
ness (poor treatment adherence) and to demonstrate a low
prevalence of EoE in patients with typical GERD symptoms
(such as heartburn and/or regurgitation) who did not
respond to an omeprazole dose of at least 40 mg.
Recently published articles corroborate the findings of the
present study.
22 Although our sample was predominantly
female, the outcome is comparable to that of other studies
that found the same results in male patients with EoE.
23
Recent evidence has shown that the eosinophil count
should not be the only criteria used to diagnose EoE.
20
Although the results are not in agreement with those
reported by other authors,
14 this discrepancy does not call
into question the validity of our results; the subjects of
previous studies may have presented with GERD with a
high eosinophil count, particularly in cases of treatment-
naı ¨ve patients or patients undergoing low-dose treatment.
Additionally, the use of five serial biopsies in patients
with persistent GERD symptoms undergoing omeprazole
treatment would increase the costs of the investigation, with
little benefit to most patients.
The high verminosis incidence among our patients is
interesting, although we did not find eosinophils infiltrating
into the digestive tract. Another important fact is that the IgE
and eosinophil levels did not differ among the patients who
did and did not present with verminosis, except among
those who had S. mansoni and S. stercoralis and consequently
developed higher levels of IgE and eosinophils, respectively.
The question is whether the population with verminosis
would be less susceptible to allergic diseases and, as
consequence, have a lower prevalence of EoE. Is there a real
difference in the prevalence of EoE among populations with
a high verminosis incidence? More research is necessary to
study the correlation between the frequency of EoE and
verminosis.
The search for additional data concerning the indications
for esophageal biopsy is very important. The literature data
and current studies demonstrate that this information could
include a history of personal or familial atopy, asthma, male
sex, young age, concerns about dysphagia or food impaction
in the esophagus and screening for endoscopic alterations,
even subtle ones.
CONCLUSION
The prevalence of eosinophilic esophagitis is low in
patients with persistent heartburn and/or regurgitation
symptoms refractory to omeprazole treatment.
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